KSI-301

Phase 3Small molecule

KKodiak Sciences Inc

KSI-301 is one of 88 small molecule programs targeting Retinal Vein Occlusion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal Vein OcclusionActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Non-Proliferative Diabetic RetinopathyActive, not recruiting

Retinal Vein OcclusionPhase 3

Active, not recruiting

Diabetic Macular EdemaPhase 3

Active, not recruiting

Age-Related Macular DegenerationPhase 3

Active, not recruiting

Non-Proliferative Diabetic RetinopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 9

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 10

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration2 trials

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Completed·KKodiak Sciences Inc·Phase 3·NCT04964089·557 enrolled

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Terminated·KKodiak Sciences Inc·Phase 2/3·NCT04049266·559 enrolled

Diabetic Macular Edema2 trials

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Terminated·KKodiak Sciences Inc·Phase 3·NCT04611152·460 enrolled

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Terminated·KKodiak Sciences Inc·Phase 3·NCT04603937·459 enrolled

Non-Proliferative Diabetic Retinopathy1 trial

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

Terminated·KKodiak Sciences Inc·Phase 3·NCT05066230·253 enrolled

Retinal Vein Occlusion1 trial

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Completed·KKodiak Sciences Inc·Phase 3·NCT04592419·568 enrolled

Systemic1 trial

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Terminated·KKodiak Sciences Inc·Phase 1·NCT03790852·121 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for KSI-301. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KSI-301 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KSI-301. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kodiak Sciences Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKodiak Sciences Inc

KSI-301

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Age-Related Macular Degeneration2 trials

Diabetic Macular Edema2 trials

Non-Proliferative Diabetic Retinopathy1 trial

Retinal Vein Occlusion1 trial

Systemic1 trial

References

Drug Info

Quick Facts

Related News